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Abstract
Background: Little is known about survival outcomes of HIV patients on first-line antiretroviral therapy (ART) on a
large-scale in India, or facility level factors that influence patient survival to guide further improvements in the ART
program in India. We examined factors at the facility level in addition to patient factors that influence survival of
adult HIV patients on ART in the publicly-funded ART program in a high- and a low-HIV prevalence state.
Methods: Retrospective chart review in public sector ART facilities in the combined states of Andhra Pradesh and
Telangana (APT) before these were split in 2014 and in Rajasthan (RAJ), the high- and a low-HIV prevalence states,
respectively. Records of adults initiating ART between 2007-12 and 2008-13 in APT and RAJ, respectively, were
reviewed and facility-level information collected at all ART centres and a sample of link ART centres. Survival
probability was estimated using Kaplan-Meier method, and determinants of mortality explored with facility and
patient-level factors using Cox proportional hazard model.
Results: Based on data from 6581 patients, the survival probability of ART at 60 months was 76.3 % (95 % CI
73.0–79.2) in APT and 78.3 % (74.4–81.7) in RAJ. The facilities with cumulative ART patient load above the state
average had lower mortality in APT (Hazard ratio [HR] 0.74, 0.57–0.95) but higher in RAJ (HR 1.37, 1.01–1.87).
Facilities with higher proportion of lost to follow-up patients in APT had higher mortality (HR 1.47, 1.06–2.05), as
did those with higher ART to pre-ART patient ratio in RAJ (HR 1.62, 1.14–2.29). In both states, there was higher
hazard for mortality in patients with CD4 count 100 cells/mm3 or less at ART initiation, males, and in patients
with TB co-infection.
Conclusions: These data from the majority of facilities in a high- and a low-HIV burden state of India over
5 years reveal reasonable and similar survival outcomes in the two states. The facilities with higher ART load in
the longer established ART program in APT had better survival, but facilities with a higher ART load and a higher
ratio of ART to pre-ART patients in the less experienced ART program in RAJ had poorer survival. These findings
have important implications for India’s ART program planning as it expands further.
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Background
Over the last decade, the HIV program in India has been
scaled up substantially to reduce mortality and morbidity
from HIV/AIDS and to improve the quality of life of
those infected by HIV. The rapid scale-up of antiretro-
viral treatment (ART) services in recent years has im-
proved access to ART with provision of free ART under
the National AIDS Control Program (NACP- IV) [1].
The HIV program in India aims for evidence-based
planning for further ART roll-out and performance
monitoring [2]. However, there is a paucity of literature
on survival outcomes of HIV patients on ART on a
large-scale in India. The available reports are based on
small samples of HIV patients, data limited to a single
treatment centre, survival outcomes with TB as comor-
bidity, or have explored only the individual level predic-
tors for survival on ART [3–7]. At the time of designing
the study in 2012-13, our aim was to document survival
outcomes and analyse the individual level and facility
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level predictors of survival for HIV patients on first-line
ART in NACP-IV in two Indian states - Andhra Pradesh
and Rajasthan. Andhra Pradesh in south India had a
population of about 85 million population at that time,
and the highest number of persons with HIV among any
Indian state with a long-standing ART program. On the
other hand, Rajasthan in north India had a population of
about 70 million, and a relatively lower HIV burden with
a more recent ART program [8]. Heterosexual mode of
transmission is the major HIV infection route in both
states [8].
Methods
After data collection was completed in 2013, the state of
Telangana was carved out of Andhra Pradesh state in
June 2014. As data were collected prior to this split, we
report findings for the undivided Andhra Pradesh that
includes the current Andhra Pradesh and Telangana
(APT) and for Rajasthan (RAJ).
Ethics approval for this study was obtained from
Ethics Committees of the Public Health Foundation of
India, New Delhi and the University of Washington,
Seattle, USA. The study was approved by the Indian
Council for Medical Research, Health Ministry Steering
Committee, the Government of India and by the
National AIDS Control Organization of India.
Sample of ART facilities
In India, ART services are provided by ART centres and
Link ART centres (LAC). ART centre provides pre-ART
and ART services to HIV infected people, and LAC is an
extension of ART centre which were established to
minimize the travel need and related costs for ART pa-
tients to receive basic ART services [8]. Patients on ART
are registered with ART centre to start treatment and
once stable are then transferred to LAC to receive medi-
cations on a routine basis. In this study, for APT all 45
ART centres and one LAC for each ART functional in
2012 were randomly sampled. A total of 41 LACs were
subsequently sampled as four ART centres in the state
capital Hyderabad had no LAC. In RAJ all 16 ART cen-
tres and all 27 link ART centres functional in 2012 were
sampled, of which 10 LAC were newly established, and
hence data were not available for these for this study.
Patient clinical record data
The ART patient’s clinical record (known as white card)
is maintained at the facilities that provide ART services.
It is used to document demographic information of the
patient; risk factors; and various treatment and clinical
details, and follow-up details for each visit. We aimed to
sample 75 and 35 adult patient records at each ART
centre and LAC, respectively in APT, for the last five fi-
nancial years at the time of starting data collection
(April 2007 to March 2012). For RAJ, the aimed sample
was 180 and 30 adult patient records at each ART centre
and LAC, respectively, during the last 5 financial years
at the time of starting data collection (April 2008 to
March 2013). With this approach, at least 3000 adult pa-
tients on ART were finally expected to be part of the
study in each state. Only records of patients who were
initiated on first line ART between 6 and 60 months
prior to the date of data collection were considered eli-
gible. We used the ART enrolment register which in-
cludes documentation of the ART initiation date for
each patient to arrive at the total number of eligible
adult patient records at each facility. We then used a
pre-defined sampling strategy to sample the eligible pa-
tient records at each ART facility - the total number of
adult patients who had initiated ART within the inclu-
sion time period was divided by the required number of
adult patient records to be sampled to arrive at the sam-
pling interval. A random number was picked within this
sampling interval to select the first record, and then the
records were sampled systematically using the sampling
interval until the desired sample was achieved.
Data collection procedure
Data were collected electronically using Datstat Illume
Survey Manager 5.1 (DatStat Inc., Seattle, WA). The
program used for capturing data was a replica of the
white card. Data extractors trained in study procedures
recorded data “as is” from the white cards to reflect the
actual data in each white card. The current status of the
patient (alive, dead, lost to follow-up, or transferred to
another facility) was recorded from the ART enrolment
register. Ten percent or more of data collected were
checked daily by the field team supervisor to ensure the
quality of data collected. Formal consent of the senior-
most person responsible at each ART facility was ob-
tained to collect these data. Data were collected in APT




The probability of survival of HIV patients on ART at 12
and 60 months was estimated using the Kaplan-Meier
product limit estimation method. The duration of sur-
vival was calculated from the month of ART initiation to
the month of death or to the last visit for the alive pa-
tients. Censoring based on the last date of visit to the
ART was done for patients who were lost to follow-up
(LFU) or transferred out of the facility. We report overall
survival probability of HIV patients on ART at 12 and
60 month for the two sexes and by baseline CD4 cell
count. As mortality at the facility level is mostly not cap-
tured among HIV patients who were LFU, we adjusted
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the survival with mortality among LFU patients as
shown in the equation below that has been previously
used in the literature: [9]
S tð Þ ¼ 1− ML tð Þ þ L tð Þ MNL tð Þ½ 
where S(t) = adjusted ART survival in last 5 years; L(t) =
Proportion of LFU patients in 5 years; ML(t) =Mortality
estimated in LFU patients; and MNL(t) =Mortality ob-
served in patients in care (1- predicted Kaplan-Meier
survival estimates).
As an inverse relation between mortality among LFU
patients and the rate of LFU in the ART program has
been previously reported from an analysis of several HIV
programs in Africa, we used the following equation from
this analysis to estimate mortality among LFU patients
in each facility in APT and RAJ: [9]
MLi ¼ exp a þ brið Þ= 1 þ exp a þ brið Þð Þ
where MLi = mortality among non-LFU patients in each
facility, r = proportion of LFU patients in each facility,
a = 0.57287 and b = −4.04409.
Finally, we calculated the weighted average of ML for
each state by using the total patients on ART in each fa-
cility in each state. The weighted average of estimated
mortality among LFU patients was 0.43 for APT and
0.61 for RAJ at 5 years. We considered 20 % lower and
higher levels than the point estimates for ML(t) for sen-
sitivity analysis for the probabilities of ART survival,
which was performed using Monte Carlo simulations by
doing 100,000 iterations with the @Risk software (Palis-
ade UK Europe Ltd). We used random values between
these plausible ranges to obtain the 95 % uncertainty
interval (UI) for the probabilities of survival estimates.
We report survival probability at 60 months that is
adjusted for LFU mortality.
Predictors of mortality
Cox proportional hazard model was used to determine
the predictors of mortality with select patient demog-
raphy and clinical indicators (ART regimen, CD4 count
at start of ART, co-existing tuberculosis, history of alco-
hol use). We also included facility related variables -
cumulative ART patient load at ART centre, ratio of
cumulative ART patients to pre-ART patients, and per-
cent of cumulative LFU patients. The cumulative data
over the 5-year study period was used to calculate the
average value for each of these variables per state. Facil-
ities were categorised as having below/equal or above
the average value for cumulative ART patient load and
ratio of cumulative ART patients to pre-ART patients;
and were categorised into three equal groups based on
the percent of cumulative LFU patients for the analysis.
For this analysis, the ART patients undergoing treatment
at LAC were considered together with the parent ART
centre which was their primary registration for ART.
The 95 % confidence intervals (CI) are reported where
relevant. The median CD4 count at the ART initiation is
presented for the alive, dead and LFU patients separately
and range is also reported. Log rank test was used to
examine the test of significance for survival probability.
Data from 82 to 41 facilities were available for analysis
in APT and RAJ, respectively. Data were analysed using
the statistical software STATA (version 13.1, StatCorp,
USA).
Results
A total of 3340 adult patient records were extracted for
analysis in APT state of which 3280 (98.2 %) records had
information available on the current status of the patient
at the time of data collection. Among these, 2130
(64.9 %) were alive and on ART, 437 (13.3 %) had died,
432 (13.2 %) were LFU, and 281 (8.6 %) were transferred
out to another ART facility during the study period. In
RAJ state, 3241 adult patient records were extracted for
analysis of which 3198 (98.7 %) had information avail-
able on the current status of the patient at the time of
data collection. Among these, 2554 (79.9 %) were alive
and on ART, 393 (12.3 %) were dead, 115 (3.6 %) were
LFU, and 136 (4.3 %) were transferred out to another
ART facility.
The demographic and clinical characteristics of adult
patients on ART are summarized in Table 1. The median
age of patients on ART was 35 years in both states (Inter-
quartile range, IQR 29–40 years). The median CD4 cell
count at ART initiation was 172 cells/mm3 (IQR 104–
236) in APT and 159 cells/mm3 (IQR 86–240) in RAJ.
Significantly more patients had CD4 count of < =100 cells/
mm3 at ART initiation in RAJ (29.4 %) than in APT
(23.4 %; p < 0.001). The patients who were alive and on
treatment showed an increasing trend in median CD4 cell
counts at ART initiation over the years in both the states
(Fig. 1). The overall baseline median CD4 cell count of de-
ceased patients [126 cells/mm3 (IQR 66–194) in APT and
93 cells/mm3 (IQR 48–159) in RAJ) were comparatively
lower than the patients who were alive and on treatment
in both the states [184 cells/mm3 (IQR 115–245) in APT
and 172 cells/mm3 (IQR 98–247) in RAJ].
Survival probability
Among the 437 and 393 patients who had died in APT
and RAJ, respectively, 188 (43 %) in APT and 191
(48.6 %) patients in RAJ had died within 6 months of
starting ART. The unadjusted mortality rate among pa-
tients on ART in APT and RAJ was 6.83 and 7.18 per
100 patient-years at 60 months, respectively. The median
survival time was 22 months in APT and 18 months in
RAJ.
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Table 1 Demographic and clinical characteristics of patients on ART, and facility-related indicators in Andhra Pradesh and Telangana
(2007-12) and in Rajasthan (2008-13)
Andhra Pradesh and Telangana (N = 3,340)a Rajasthan (N = 3,241)b
Variables Total (% of N) Deceased (%) Total (% of N) Deceased (%)
Patient level
Year of ART initiationc
2007-08 365 (10.9) 58 (15.9)
2008-09 458 (13.7) 68 (14.9) 422 (13.0) 72 (17.1)
2009-10 767 (23.0) 97 (12.7) 651 (20.1) 67 (10.3)
2010-11 829 (24.8) 124 (15.0) 749 (23.1) 90 (12.0)
2011-12 919 (27.5) 90 (9.8) 850 (26.2) 85 (10.0)
2012-13 569 (17.6) 79 (13.9)
Sex of patient
Male 1,724 (51.6) 273 (15.8) 1,860 (57.4) 285 (15.3)
Female 1,561 (46.7) 159 (10.2) 1,360 (42.0) 108 (7.9)
Age of patients (years)
16–29 857 (25.7) 98 (11.4) 720 (22.2) 66 (9.2)
30–49 2,152 (64.4) 287 (13.3) 2,250 (69.4) 278 (12.4)
= >50 329 (9.9) 52 (15.8) 271 (8.4) 49 (18.1)
CD4 count at ART initiation (cells/mm3)
< =100 782 (23.4) 168 (21.5) 954 (29.4) 209 (21.9)
101–250 1,870 (56.0) 226 (12.1) 1,562 (48.2) 150 (9.6)
>250 659 (19.7) 41 (6.2) 696 (21.5) 31 (4.5)
Co-existing tuberculosis
No 2,823 (84.5) 336 (11.9) 2,582 (79.7) 276 (10.7)
Yes 515 (15.4) 101 (19.6) 627 (19.4) 117 (18.7)
Ever use of alcohol
No 2,739 (82.0) 319 (11.7) 2,709 (83.6) 299 (11.0)
Yes 599 (17.9) 118 (19.7) 519 (16.0) 94 (18.1)
Baseline ART regimend
STV based regimen with/without EFV 1,377 (41.2) 215 (15.6) 832 (25.7) 146 (17.6)
ZDV based regimen with/without EFV 1,542 (46.2) 166 (10.8) 2,131 (65.8) 205 (9.6)
Facility level variables
Cumulative ART patient loade
Below or equal to state average 1,891 (56.6) 262 (13.9) 1,621 (50.0) 190 (11.7)
Above state average 1,449 (43.4) 175 (12.1) 1,620 (50.0) 203 (12.5)
Ratio of cumulative ART patients to pre-ART patientsf
Below or equal to state average 1,998 (59.8) 275 (13.8) 2,433 (75.1) 271 (11.1)
Above state average 1,342 (40.2) 162 (12.1) 808 (24.9) 122 (15.1)
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The estimated unadjusted survival probability on ART
at 12 and 60 months was 91.2 % (95 % CI 90.1–92.1)
and 76.3 % (95 % CI 73.0–79.2) in APT, respectively;
and 90.6 % (95 % CI 89.4–91.6) and 78.3 % (95 % CI
74.4–81.7) in RAJ (Fig. 2). The probability of survival
was higher among females than males in both states (log
rank test, p < 0.001; Fig. 2), and was significantly lower
for patients with CD4 count <101 cells/mm3 at ART ini-
tiation than those with CD4 count >250 cells/mm3 in
both the states (log rank test, p < 0.001; Fig. 3). After
adjusting for the assumed higher mortality among LFU,
the adjusted survival probability on ART at 60 months
was 70.6 % (95 % UI 67.0–73.8) in APT and 76.1 %
(95 % UI 72.2–79.6) in RAJ.
Predictors of mortality
Table 2 shows the results with the Cox proportional haz-
ard model for the predictors of mortality among HIV
patients on ART. The findings at the patient level for
both the states were similar. Patients with CD4 count
<101 cells/mm3 at ART initiation had a higher hazard
for mortality than patients with CD4 count >250 cells/
mm3 (HR 3.36, 95 % CI 2.29–4.95 in APT and HR 3.71,
95 % CI 2.47–5.58 in RAJ). Patients with history of alco-
hol consumption had significantly higher risk of dying
than who never consumed alcohol in APT (HR 1.57,
95 % CI 1.22–2.02) and in RAJ (HR 1.42, 95 % CI 1.09–
1.86). Males as compared with females, and patients
with TB co-infection had a higher hazard for death. The
patients on Zidovudine-based ART regimen had a lower
hazard for mortality than those on the Stavudine-based
ART regimen in both states.
At the facility level, facilities with a cumulative ART
patient load above the average for the state facilities had
lower mortality in APT (HR 0.74, 95 % CI 0.57–0.95)
but had higher mortality in RAJ (HR 1.37, 95 % CI 1.01–
1.87). The facilities in APT with proportion of LFU pa-
tients higher than the state average had significantly
higher mortality (HR 1.47, 95 % CI 1.06–2.05); the trend
in RAJ was similar but did not reach statistical
Table 1 Demographic and clinical characteristics of patients on ART, and facility-related indicators in Andhra Pradesh and Telangana
(2007-12) and in Rajasthan (2008-13) (Continued)
Percent of cumulative loss to follow-up patients g
Category 1 1,070 (32.0) 123 (11.5) 1,352 (41.7) 174 (12.9)
Category 2 1,090 (32.6) 148 (13.4) 1,375 (42.4) 150 (10.9)
Category 3 1,180 (35.3) 166 (14.1) 514 (15.9) 69 (13.4)
aData missing for Andhra Pradesh and Telangana: year of ART initiation for 2; sex of patients for 55; age of patients for 2; CD4 count at ART initiation for 29;
co-existing tuberculosis for 2; ever use of alcohol for 2; baseline ART regimen for 421
bData missing for Rajasthan: sex of patients for 21; CD4 count at ART initiation for 29; co-existing tuberculosis for 32; ever use of alcohol for 13; baseline ART
regimen for 278
cFinancial year
dSTV is Stavudine, ZDV is Zidovudine, and EFV is Efavirenz
eAverage for Andhra Pradesh and Telangana is 4844 and 4307 for Rajasthan
fFor Andhra Pradesh and Telangana is 0.59 and 0.70 for Rajasthan
gThe categories for Andhra Pradesh and Telangana are <5.6 %, >5.6–8.4 % and >8.4 %; and <3.1 %, 3.1–6.5 % and >6.5 % for Rajasthan
Fig. 1 Yearly trends in baseline median CD4 cell counts for HIV patients on ART in Andhra Pradesh and Telangana (2007-12) and in Rajasthan
(2008-13) based on current status of the patient
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significance. On the other hand, facilities in RAJ with
higher ART to pre-ART patient ratio had a significantly
higher hazard for mortality (HR 1.62, 95 % CI 1.14–
2.29).
Discussion
As public sector facilities provide ART to most patients
in India, this sample of over 6500 adult patients on ART
in two major states is fairly representative of a high and
a low HIV burden state in India. This analysis of data
covering 5 years reveals that the overall survival prob-
ability of HIV patients on ART at 60 months was rea-
sonable at 76–78 %, and that the survival rates were
similar in the high- and low-HIV burden states, with the
former having a longer standing public funded ART pro-
gram in place.
The survival rates in our data at 60 months are similar
to those reported previously from three centres in south-
ern India [3, 10]. Consistent with the published litera-
ture, a significant proportion of deaths occurred within
the first 6 months of ART initiation [3–5, 7, 11]. Poor
survival of males on ART as compared with females in
our population has been documented previously from
India and elsewhere [3, 6, 12–16]. Factors such as poor
treatment seeking behaviour and non-adherence to
treatment, and increased risk of LFU have been reported
previously as possible reasons for higher mortality
among males on ART [17–20]. The median CD4 count
at ART initiation was lower for males than females in
both the states, and 58 % of LFU in APT and 65 % in
RAJ were males in our study. This finding suggests that
it would be useful for the HIV services to make males
Fig. 2 Kaplan-Meier unadjusted survival curve for HIV patients on ART for males and females in Andhra Pradesh and Telangana (2007-12) and
Rajasthan (2008-13)
Fig. 3 Kaplan-Meier unadjusted survival curve for HIV infected patients on ART by CD4 count at ART initiation (cells/mm3) in Andhra Pradesh and
Telangana (2007-12) and Rajasthan (2008-13)
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more aware of the benefits of timely initiation of ART
for better survival outcome. Both a low CD4 count at
ART initiation and co-existing TB have been previously
reported to be associated with poorer survival outcomes
among Indian patients [3, 4, 17, 21–23]. The overall
median CD4 count at ART initiation in this study had
increased significantly over the 5 years in both APT (154
to 193) and RAJ (132 to 174). However, these data were
not for those who had died. As a lower CD4 count is as-
sociated with delayed ART initiation and with higher
Table 2 Determinants of mortality among HIV patients on ART using Cox proportional hazard model for Andhra Pradesh and
Telangana (2007-12) and Rajasthan (2008-13). CI denotes confidence interval
Andhra Pradesh and Telanganaa Rajasthanb
Variables Hazard ratio (95 % CI) Hazard ratio (95 % CI)
Patient level variables
Sex of patient
Male 1.36 (1.06–1.73) 1.83 (1.41–2.38)
Female 1.00 1.00
Age of patients (years)
16–29 1.00 1.00
30–49 1.00 (0.77–1.29) 1.00 (0.75–1.34)
= >50 1.24 (0.85–1.79) 1.25 (0.84–1.88)
CD4 count at ART initiation (cells/mm3)
< =100 3.36 (2.29–4.95) 3.71 (2.47–5.58)




Yes 1.42 (1.11–1.81) 1.31 (1.04–1.67)
Ever use of alcohol
No 1.00 1.00
Yes 1.57 (1.22–2.02) 1.42 (1.09–1.86)
Baseline ART regimenc
STV based regimen with/without EFV 1.00 1.00
ZDV based regimen with/without EFV 0.67 (0.55–0.83) 0.62 (0.50–0.78)
Facility level variables
Cumulative ART patient loadd
Below or equal to state average 1.00 1.00
Above state average 0.74 (0.57–0.95) 1.37 (1.01–1.87)
Ratio of cumulative ART patients to pre-ART patientse
Below or equal to state average 1.00 1.00
Above state average 0.90 (0.71–1.15) 1.62 (1.14–2.29)
Percent of cumulative loss to follow-up patientsf
Category 1 1.00 1.00
Category 2 1.16 (0.87–1.54) 1.22 (0.94–1.58)
Category 3 1.47 (1.06–2.05) 1.40 (1.00–1.95)
aData missing for Andhra Pradesh and Telangana: year of ART initiation for 2; sex of patients for 55; age of patients for 2; CD4 count at ART initiation for 29;
co-existing tuberculosis for 2; ever use of alcohol for 2; baseline ART regimen for 421
bData missing for Rajasthan: sex of patients for 21; CD4 count at ART initiation for 29; co-existing tuberculosis for 32; ever use of alcohol for 13; baseline ART
regimen for 278
cSTV is Stavudine, ZDV is Zidovudine, and EFV is Efavirenz
dAverage for Andhra Pradesh and Telangana is 4844 and 4307 for Rajasthan
eFor Andhra Pradesh and Telangana is 0.59 and 0.70 for Rajasthan
fThe categories for Andhra Pradesh and Telangana are <5.6 %, >5.6–8.4 % and >8.4 %; and <3.1 %, 3.1–6.5 % and >6.5 % for Rajasthan
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attrition while on treatment, [17, 22] the program could
focus more on ensuring adherence and follow-up of the
patients with lower CD4 count to further improve the
survival outcomes. With regard to TB, NACP-IV has
clearly identified HIV-TB coordination including cross-
referral, detection and treatment as one of the objectives
in the revised strategy that aims to further the integra-
tion between HIV and TB services, [24] in particular to
prevent LFU and early initiation of ART [25–27].
Inclusion of data from a large number of facilities in
this study allowed assessment of facility-level variables
that influence survival on ART. These findings are rele-
vant for program planning. The ART patient load was
an important predictor of mortality in both states, albeit
differently. In APT, facilities with a higher load had bet-
ter survival outcomes possibly because of a longer estab-
lished ART program that has likely acquired more
experience leading to better outcomes. However, in RAJ,
facilities with higher ART patient load had poorer sur-
vival outcome, as did facilities with a higher ratio of
ART to pre-ART patients. This higher patient load in
the less experienced ART program in RAJ may be result-
ing in difficulty in handling patients, which indicates the
need for strengthening facilities in RAJ with high or in-
creasing ART load through monitoring of their human
resources, supplies and infrastructure. In addition, even
though both states had more pre-ART than ART pa-
tients across the facilities, the average ART to pre-ART
patient ratio was relatively higher in RAJ.
The reasonable survival outcomes in the two states,
which were not significantly different from each other
without and with adjusting for mortality in the LFU pa-
tients, are encouraging for the national HIV program.
Over the study period, the LFU proportion remained fairly
consistent in APT, and was similar to that reported previ-
ously [17, 22]. Factors associated with poor patient reten-
tion have been documented for APT, [17, 22] and more
effective and robust tracking of LFU is needed to improve
survival outcomes. The significantly lower proportion of
LFU in RAJ was a likely a result of a recent exercise car-
ried out by the State AIDS Control Society to trace LFUs
in order to bring them back to the treatment cycle. It is
possible that some LFU patients may have initiated ART
at another facility. However, it is not possible to track mo-
bility of individual patients between the ART facilities in
the program yet. To address this challenge, NACO is con-
sidering use of SMART cards with biometric identification
for each patient which could facilitate not only tracking of
patients but also potentially improve adherence and access
to treatment [28].
Our study limitations include missing data, non-usable
information on treatment adherence in the white cards,
and survival status of transferred out and LFU patients as
these were not readily available in the patient records.
Despite these limitations, these large sample data collected
from routine patient records are generalizable as all ART
centres in both states were included. Data utilised for this
study were obtained from paper forms/registers used in
routine service conditions by the providers in the facilities,
and thus are reflective of the ground reality.
Conclusions
In conclusion, these data have highlighted the benefits of
investment in ART in India which is associated with a rea-
sonably good over survival rate at 5 years, and have identi-
fied important determinants of survival on ART at the
facility-level in addition to patient-level factors that can in-
form improvement of the ART services in India. An im-
portant program-relevant message from these findings is
that ART survival could potentially be improved further if
facilities with higher load get specific attention in the initial
phase in Indian states with a more recent ART program.
Abbreviations
AIDS: Acquired immunodeficiency syndrome; APT: Andhra Pradesh and
Telangana; ART: Antiretroviral therapy; CI: Confidence interval; HIV: Human
immunodeficiency virus; HR: Hazard ratio; LAC: Link ART centre; LFU: Lost to
follow-up; NACP: National AIDS Control Programme; NACO: National AIDS
Control Organisation; UI: Uncertainty interval; RAJ: Rajasthan; TB: Tuberculosis
Acknowledgments
The authors would like to acknowledge all individuals who contributed to
this study, including the State AIDS Control Societies and facility staff who
gave their time for facilitating access to white cards and to complete survey
components; and the field team members who conducted data collection.
Funding
Funding for this work was provided by the Bill & Melinda Gates Foundation.
Availabilty of data and material
Data are available with the corresponding author, and can be made
available on request.
Authors’ contributions
RD, LD, BBR, GAK, ST and EG were responsible for the study design. SGPK
and SPR were responsible for overseeing data collection. GAK and VVS were
responsible for data management. RD, GAK, SGPK, VVS and ST were involved
with data analysis. RD and GAK drafted the original manuscript. LD, BBR, HD
and EG gave significant inputs for analysis and interpretation. All authors had
full access to the data, and have read and approved the final manuscript.
Competing interest
BBR and ST are affiliated with the Department of AIDS Control, Ministry of
Health and Family Welfare, Government of India that oversees the ART
Programme in India. LD is on the Editorial Board for the journal BMC Medicine.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Ethics approval for this study was obtained from Ethics Committees of the
Public Health Foundation of India, New Delhi and the University of
Washington, Seattle, USA. The study was also approved by the Indian
Council for Medical Research, Health Ministry Steering Committee, the
Government of India and by the National AIDS Control Organization of India.
As the data collection involved retrospective review of patient records with
no identifiable information to be collected, the consent to participate from
patients was exempted by the Ethics Committee as this research was
designed to study benefit of a public service programme.
Dandona et al. BMC Infectious Diseases  (2016) 16:555 Page 8 of 9
Author details
1Public Health Foundation of India, New Delhi, India. 2Department of AIDS
Control, Ministry of Health and Family Welfare, Government of India, New
Delhi, India. 3World Health Organization Country Office for India, New Delhi,
India. 4Institute for Health Metrics and Evaluation, University of Washington,
Seattle, Washington, USA.
Received: 18 May 2016 Accepted: 1 October 2016
References
1. NACP-IV components. [http://www.naco.gov.in/nacp-iv-components].
Accessed 5 Oct 2016.
2. NACP-IV Programme Priorities and Thrust Areas. [http://www.naco.gov.in/
programme-priorities-and-thrust-areas-0]. Accessed 5 Oct 2016.
3. Allam RR, Murhekar MV, Bhatnagar T, Uthappa CK, Chava N, Rewari BB,
Venkatesh S, Mehendale S. Survival probability and predictors of mortality
and retention in care among patients enrolled for first-line antiretroviral
therapy, Andhra Pradesh, India, 2008-2011. Trans R Soc Trop Med Hyg.
2014;108(4):198–205.
4. Bachani D, Garg R, Rewari BB, Hegg L, Rajasekaran S, Deshpande A,
Emmanuel KV, Chan P, Rao KS. Two-year treatment outcomes of patients
enrolled in India’s national first-line antiretroviral therapy programme. Natl
Med J India. 2010;23(1):7–12.
5. Ghate M, Deshpande S, Tripathy S, Godbole S, Nene M, Thakar M, Risbud A,
Bollinger R, Mehendale S. Mortality in HIV infected individuals in Pune, India.
Indian J Med Res. 2011;133:414–20.
6. Rajeev A, Sharma A. Mortality and morbidity patterns among HIV patients
with prognostic markers in a tertiary care hospital in southern India.
Australa Med J. 2011;4(5):273–6.
7. Sharma SK, Dhooria S, Prasad KT, George N, Ranjan S, Gupta D, Sreenivas V,
Kadhiravan T, Miglani S, Sinha S, et al. Outcomes of antiretroviral therapy in
a northern Indian urban clinic. Bull World Health Organ. 2010;88(3):222–6.
8. NACO Annual Report 2014-15. [http://www.naco.gov.in/sites/default/files/
annual_report%20_NACO_2014-15_0.pdf]. Accessed 5 Oct 2016.
9. Egger M, Spycher BD, Sidle J, Weigel R, Geng EH, Fox MP, MacPhail P, van
Cutsem G, Messou E, Wood R, et al. Correcting mortality for loss to
follow-up: a nomogram applied to antiretroviral treatment programmes in
sub-Saharan Africa. PLoS Med. 2011;8(1):e1000390.
10. Ghate M, Tripathy S, Gangakhedkar R, Thakar M, Bhattacharya J, Choudhury
I, Risbud A, Bembalkar S, Kadam D, Rewari BB, et al. Use of first line
antiretroviral therapy from a free ART programme clinic in Pune, India - A
preliminary report. Indian J Med Res. 2013;137(5):942–9.
11. Rajasekaran S, Jeyaseelan L, Raja K, Vijila S, Krithigaipriya KA, Kuralmozhi R.
Increase in CD4 cell counts between 2 and 3.5 years after initiation of
antiretroviral therapy and determinants of CD4 progression in India.
J Postgrad Med. 2009;55(4):261–6.
12. Druyts E, Dybul M, Kanters S, Nachega J, Birungi J, Ford N, Thorlund K,
Negin J, Lester R, Yaya S, et al. Male sex and the risk of mortality among
individuals enrolled in antiretroviral therapy programs in Africa: a systematic
review and meta-analysis. AIDS. 2013;27(3):417–25.
13. Rai S, Mahapatra B, Sircar S, Raj PY, Venkatesh S, Shaukat M, Rewari BB.
Adherence to Antiretroviral Therapy and Its Effect on Survival of HIV-
Infected Individuals in Jharkhand, India. PLoS One. 2013;8(6):e66860.
14. Sieleunou I, Souleymanou M, Schönenberger AM, Menten J, Boelaert M.
Determinants of survival in AIDS patients on antiretroviral therapy in a rural
centre in the Far-North Province, Cameroon. Trop Med Int Health.
2009;14(1):36–43.
15. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, Mtonga V, Reid S,
Cantrell RA, Bulterys M, et al. Rapid scale-up of antiretroviral therapy at
primary care sites in Zambia: feasibility and early outcomes. JAMA.
2006;296(7):782–93.
16. Mills EJ, Bakanda C, Birungi J, Chan K, Hogg RS, Ford N, Nachega JB, Cooper
CL. Male gender predicts mortality in a large cohort of patients receiving
antiretroviral therapy in Uganda. J Int AIDS Soc. 2011;14:52.
17. Alvarez-Uria G, Naik PK, Pakam R, Midde M. Factors associated with attrition,
mortality, and loss to follow up after antiretroviral therapy initiation: data
from an HIV cohort study in India. Glob Health Action. 2013;6:21682.
18. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, Chaisson
RE, Maartens G. Adherence to highly active antiretroviral therapy assessed
by pharmacy claims predicts survival in HIV-infected South African adults.
J Acquir Immune Defic Syndr. 2006;43(1):78–84.
19. Ochieng-Ooko V, Ochieng D, Sidle JE, Holdsworth M, Wools-Kaloustian K,
Siika AM, Yiannoutsos CT, Owiti M, Kimaiyo S, Braitstein P. Influence of
gender on loss to follow-up in a large HIV treatment programme in
western Kenya. Bull World Health Organ. 2010;88(9):681–8.
20. Cornell M, Schomaker M, Garone DB, Giddy J, Hoffmann CJ, Lessells R,
Maskew M, Prozesky H, Wood R, Johnson LF, et al. Gender differences in
survival among adult patients starting antiretroviral therapy in South Africa:
a multicentre cohort study. PLoS Med. 2012;9(9):e1001304.
21. Bhowmik A, Bhandari S, De R, Guha SK. Predictors of mortality among
HIV-infected patients initiating anti retroviral therapy at a tertiary care
hospital in eastern India. Asian Pac J Trop Med. 2012;5(12):986–90.
22. Alvarez-Uria G, Pakam R, Midde M, Naik PK. Predictors of delayed
antiretroviral therapy initiation, mortality, and loss to followup in HIV
infected patients eligible for HIV treatment: data from an HIV cohort study
in India. Biomed Res Int. 2013;2013:849042.
23. Rupali P, Mannam S, Bella A, John L, Rajkumar S, Clarence P, Pulimood SA,
Samuel P, Karthik R, Abraham OC, et al. Risk factors for mortality in a south
Indian population on generic antiretroviral therapy. J Assoc Physicians India.
2012;60:11–4.
24. NACP IV Strategy document. [http://www.naco.gov.in/sites/default/files/
Strategy_Document_NACP%20IV.pdf]. Accessed 5 Oct 2016.
25. Gupta AK, Singh GP, Goel S, Kaushik PB, Joshi BC, Chakraborty S. Efficacy of
a new model for delivering integrated TB and HIV services for people living
with HIV/AIDS in Delhi – case for a paradigm shift in national HIV/TB cross-
referral strategy. AIDS Care. 2014;26(2):137–41.
26. Vijay S, Kumar P, Chauhan LS, Rao SV, Vaidyanathan P. Treatment outcome
and mortality at one and half year follow-up of HIV infected TB patients
under TB control programme in a district of South India. PLoS One.
2011;6(7):e21008.
27. Vijay S, Swaminathan S, Vaidyanathan P, Thomas A, Chauhan LS, Kumar P,
Chiddarwar S, Thomas B, Dewan PK. Feasibility of provider-initiated HIV
testing and counselling of tuberculosis patients under the TB control
programme in two districts of South India. PLoS One. 2009;4(11):e7899.
28. National AIDS Control Programme. Journey of ART programme in India:
story of a decade. New Delhi:Ministry of Health and Family Welfare,
Government of India; 2014.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Dandona et al. BMC Infectious Diseases  (2016) 16:555 Page 9 of 9
